Insulin-Like Growth Factor-1 Promotes Wound Healing in Estrogen-Deprived Mice: New Insights into Cutaneous IGF-1R/ERα Cross Talk  by Emmerson, Elaine et al.
Insulin-Like Growth Factor-1 Promotes Wound
Healing in Estrogen-Deprived Mice: New Insights
into Cutaneous IGF-1R/ERa Cross Talk
Elaine Emmerson1, Laura Campbell1, Faith C.J. Davies1, Nina L. Ross1, Gillian S. Ashcroft1, Andre´e Krust2,
Pierre Chambon2 and Matthew J. Hardman1
Although it is understood that endogenous IGF-1 is involved in the wound repair process, the effects of
exogenous IGF-1 administration on wound repair remain largely unclear. In addition, the signaling links
between IGF-1 receptor (IGF-1R) and estrogen receptors (ERs), which have been elucidated in other systems,
have yet to be explored in the context of skin repair. In this study, we show that locally administered IGF-1
promotes wound repair in an estrogen-deprived animal model, the ovariectomized (Ovx) mouse, principally by
dampening the local inflammatory response and promoting re-epithelialization. Using specific IGF-1R and ER
antagonists in vivo, we reveal that IGF-1-mediated effects on re-epithelialization are directly mediated by IGF-1R.
By contrast, the anti-inflammatory effects of IGF-1 are predominantly via the ERs, in particular ERa. Crucially, in
ERa-null mice, IGF-1 fails to promote healing, and local inflammation is increased. Our findings illustrate the
complex interactions between IGF-1 and estrogen in skin. The fact that IGF-1 may compensate for estrogen
deficiency in wound repair, and potentially other contexts, is an important consideration for the treatment of
postmenopausal pathology.
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INTRODUCTION
Data on the effects of IGF-1 on wound repair are somewhat
conflicting. IGF-1 is wound induced in both animals (Bos
et al., 2001) and humans (Gartner et al., 1992; Todorovic
et al., 2008) but lacking in chronic wounds (Toulon et al.,
2009), yet several porcine studies report that local IGF-1
augmentation fails to improve excisional wound healing
(Lynch et al., 1989; Breuing et al., 1997). More recently,
however, overexpression of locally acting IGF-1 under the K14
promoter has been demonstrated to enhance murine healing
(Semenova et al., 2008). In addition, locally delivered IGF-1
accelerates healing in senescent mice (Koshizuka et al., 1997)
and in a rat tissue ischemia model (Beckert et al., 2005). In
vitro IGF-1 enhances the proliferation and migration of both
keratinocytes and fibroblasts (Tavakkol et al., 1992; Ando and
Jensen, 1993; Bhora et al., 1995; Telasky et al., 1998; Haase
et al., 2003). It is of clinical relevance that IGF-1 is reduced in
cells isolated from diabetic foot ulcers (Blakytny et al., 2000)
and diabetic mouse wounds (Brown et al., 1997), whereas
IGF-1 treatment or overexpression promotes healing in
diabetic animals (Bitar, 1997; Hirsch et al., 2008).
With increasing age, skin undergoes substantial changes
that result in delayed healing. We and others have strongly
implicated hormonal changes in this healing delay (reviewed
in Emmerson and Hardman, 2012), particularly reduced
estrogen post menopause (Ashcroft et al., 2003; Hardman
and Ashcroft, 2008). Replacement of estrogen or estrogenic
compounds reverses this delay (Ashcroft et al., 1997, 1999;
Hardman et al., 2008; Emmerson et al., 2010), whereas
systemic estrogen has actually been shown to reduce the risk
of developing chronic wounds (Margolis et al., 2002).
Unfortunately, influential reports linking estrogen replace-
ment (hormone replacement therapy) to adverse effects
(Anderson et al., 2004; Banks et al., 2004) have led to
markedly reduced therapeutic use of estrogen (Faber et al.,
2005). As there are currently limited treatments for chronic
wounds (reviewed in Ubbink et al., 2008; Jones, 2009),
hormone-based therapy may be a viable option.
Interestingly, age negatively correlates with serum levels of
both IGF-1 and estrogen in humans, particularly females
(Labrie et al., 1997; Leifke et al., 2000; Tanimoto et al., 2008).
IGF-1 increases following 17b-estradiol exposure in rodent
uterus (Murphy et al., 1987; Kapur et al., 1992), and IGF-1
can directly stimulate phosphorylation of the estrogen
receptor (ER) to induce transcription in the absence of
17b-estradiol (Aronica and Katzenellenbogen, 1993), whereas
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IGF-1 receptor (IGF-1R) and ER cross talk has been reported in
the uterus (Klotz et al., 2000, 2002) and brain (Marin et al.,
2009). Surprisingly, potential cross talk between IGF-1/IGF-1R
and 17b-estradiol/ER has not been explored in the skin.
Moreover, the effect of local IGF-1 administration on healing
of hormonally deprived rodents has yet to be investigated. In
this study, we reveal that IGF-1 can potentially compensate for
the lack of 17b-estradiol in ovariectomized (Ovx) mice.
Intriguingly, in vivo experiments using antagonists to IGF-1R
and/or ERs suggest involvement of both in IGF-1’s healing-
promoting effects.
RESULTS
IGF-1 promotes cutaneous healing in estrogen-deprived mice
The Ovx mouse has been extensively used as a model of
postmenopausal pathology (Kalu and Chen, 1999; Dubal
et al., 2001). With respect to the skin, Ovx mice display a
pronounced delay in healing, which we have previously been
able to reverse via the systemic restoration of endogenous
17b-estradiol levels (Hardman et al., 2008; Campbell et al.,
2010; Emmerson et al., 2010). Here, we find that treatment of
Ovx mice with local IGF-1 also promotes healing (reduction
in wound area) to a level that is comparable to systemic 17b-
estradiol treatment (Figure 1a and c). Similarly, both IGF-1
and 17b-estradiol promoted re-epithelialization (Figure 1b
and c). Our previous studies have shown that 17b-estradiol is
potently anti-inflammatory during healing (Ashcroft et al.,
1997, 1999; Hardman et al., 2008; Campbell et al., 2010;
Emmerson et al., 2010). Here, we demonstrate previously
unreported skin anti-inflammatory activity for IGF-1 during
healing, significantly reducing wound neutrophil and macro-
phage influx in Ovx mice to the same extent as 17b-estradiol
(Figure 1d and e).
The IGF-1R antagonist JB3 differentially influences local
inflammation and healing outcome depending on the route of
administration
Wound IGF-1 and IGF-1R expression was determined in
tissue from intact mice and untreated, 17b-estradiol-treated,
and IGF-1-treated Ovx mice. Although we observed no
difference in wound tissue IGF-1 (not shown), local IGF-1
supplementation significantly increased dermal IGF-1R levels
(Figure 2a and b). This led us to ask whether IGF-1R
contributed to IGF-1’s effects on wound healing. Local
cotreatment with the IGF-1R antagonist JB3 (Haylor et al.,
2000) entirely abolished the beneficial effects of IGF-1 on
healing, increasing the wound area and reducing re-
epithelialization to vehicle-treated Ovx levels (Figure 2c–e).
Interestingly, the effects of local JB3 on healing parameters
occurred in the absence of any influence on IGF-1’s anti-
inflammatory activity (i.e., local JB3 failed to alter IGF-1
reduction in neutrophils and macrophages; Figure 2f and g).
By contrast, cotreatment with systemic JB3 had little effect on
IGF-1-promoted healing outcome (Figure 2c–e; wound area
and re-epithelialization) but, crucially, did alter the anti-
inflammatory activity of IGF-1, significantly increasing
macrophage influx compared with IGF-1 alone (Figure 2g).
Intriguingly, systemic antagonism of endogenous IGF-1 in
Ovx mice (i.e., JB3 treatment alone) significantly increased
macrophage influx compared with the Ovx mice (Figure 2g).
IGF-1 modulates local ER expression, with IGF-1 effects on
healing being partially ER dependent
Estrogenic ligands signal by binding heterodimers and
homodimers of ERs (ERa and ERb; reviewed in Heldring
et al., 2007). Here we show that IGF-1 supplementation in
estrogen-deprived mice specifically induced cellular ERb
protein levels (Figure 3b and f). Moreover, IGF-1 failed to
induce local ERa protein levels (Figure 3a and e), again
mirroring the effects of 17b-estradiol (data not shown;
Emmerson et al., 2010). Similarly, in wound-edge epidermis,
ERb but not ERa expression was preferentially induced by
IGF-1 compared with vehicle (Figure 3c, d, g and h). To
confirm a functional role for ERs in IGF-1-mediated healing
promotion, we cotreated wounds with IGF-1 and the ER
antagonist ICI 182780. ICI partially, but significantly, reversed
IGF-1-promoted healing, measured via wound area (Figure
3i), but failed to influence re-epithelialization (Figure 3j). Of
importance, ICI at the same concentration entirely reversed
17b-estradiol’s beneficial effects on healing (Emmerson et al.,
2010). ICI also partially reversed the effect of IGF-1 on
macrophage, but not neutrophil, influx (Figure 3k and l).
IGF-1-mediated promotion of healing in vivo requires ERa
Although 17b-estradiol replacement promotes healing in Ovx
mice (Hardman et al., 2008; Emmerson et al., 2010) and in
ERa/ mice (Campbell et al., 2010), in mice lacking ERb
(ERb/) 17b-estradiol treatment further delays healing (Camp-
bell et al., 2010). By contrast, local IGF-1 treatment improved
healing in ERb/ mice (as in wild-type mice), yet had no
effect on healing in ERa/ mice (Figure 4a and d). Thus, ER-
null mice differ in their response to local IGF-1 treatment, and
in each case (ERa/ and ERb/) the effect on healing is
opposite to 17b-estradiol treatment (Campbell et al., 2010).
Interestingly, these phenotypes cannot be attributed to altered
re-epithelialization (Figure 4b and d), but instead directly
mirror changes in wound macrophage numbers. Specifically,
IGF-1 reduces wound macrophage recruitment in wild-type
and ERb/ mice, whereas in IGF-1-treated ERa/ wounds
macrophage numbers are further increased compared with the
hyper-inflammatory Ovx control (Figure 4c). Thus, excessive
inflammation appears to be a key factor in the delayed healing
of IGF-1-treated ERa/ mice.
Cell-specific ERa-null mice reveal complex roles for IGF-1
in vivo
To expand upon our observations of altered healing in IGF-1-
treated global ERa/ mice, we generated cell-specific
conditional null mice lacking ERa in either the epidermis
(K14;ERa/) or inflammatory cells (LysM;ERa/). IGF-1
treatment of Ovx K14;ERa/ mice failed to promote healing
(i.e., no reduction in wound area or promotion of re-
epithelialization; Figure 5a, b and d), unlike wild-type
littermate controls. Moreover, this failure in Ovx K14;ERa/
mice correlated with increased local inflammation
(macrophages; Figure 5c and e). This directly contrasts with
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17b-estradiol treatment, which promotes healing in Ovx
K14;ERa/ (Campbell et al., 2010). Surprisingly, IGF-1
treatment of inflammatory cell–specific conditional null mice
(LysM;ERa/) resulted in reduced wound area (Figure 5a and
d), despite high levels of inflammation (Figure 5c and e)
accompanied by detrimental paracrine effects on keratino-
cyte re-epithelialization (Figure 5b).
Cell-specific roles for IGF-1R and ERs are confirmed in vitro
IGF-1 (at doses of 107, 108, 109 M) promoted primary
human keratinocyte migration across an artificial scratch
(Figure 6a and c, data not shown). Cotreatment with the IGF-
1R antagonist JB3, but not the ERa-selective or ERb-selective
antagonists (MPP and PHTPP), significantly reduced scratch
wound closure (Figure 6a and c). These data mirror the
observed inhibition of re-epithelialization after IGF-1R
antagonism in vivo (Figure 2d), and strongly suggest that
the effect of IGF-1 on keratinocyte migration is mediated by
IGF-1R. IGF-1 (107, 108, 109 M) also promoted primary
human fibroblast scratch wound migration (Figure 6b and d,
data not shown). In addition, the insulin receptor antagonist
HNMPA-(AM)3 at 200mM (Saperstein et al., 1989) did not
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Figure 1. Local IGF-1 promotes cutaneous healing in estrogen-deprived mice. Local IGF-1 accelerates healing to an extent equal to systemic 17b-estradiol
(þ E2) replacement, quantified by (a) a significant reduction in wound area and (b) increase in re-epithelialization versus untreated ovariectomized (Ovx) mice.
(c) Representative hematoxylin and eosin–stained sections of incisional wounds (day 3). Arrows indicate wound margins. IGF-1 reduces (d) wound neutrophil
and (e) macrophage numbers to a similar extent as 17b-estradiol–treated wounds. Meanþ SEM, n¼6 per group. *Po0.05, **Po0.01. Bar¼500 mm.
2840 Journal of Investigative Dermatology (2012), Volume 132
E Emmerson et al.
IGF-1 Promotes Cutaneous Healing in Ovx Mice
IGF-1R
8
6
4
2
0
Intact
Wound area % Re-epithelialization
2.5 100
*
* *
80
60
% 40
20
0
*
* *2
1.5
1
0.5A
re
a 
(m
m2
)
0
–
–
– –
–
+ +
+
+
++–
– –
– –
–
– –
–
+ +
+
+
++–
– –
–IGF-1
JB3 (loc)
JB3 (sys)
Intact
Ovx
Ovx
+E2 +E2+IGF-1 +IGF-1
Ce
lls
 p
er
 m
m
2  
(×1
00
)
*
*
*
Ovx+IGF-1 Ovx+IGF-1+local JB3
Ovx+IGF-1+systemic JB3 Ovx+systemic JB3
Neutrophils
10 15
*
*
*
*
10
5
0
8
6
4
2
0C
el
ls 
pe
r m
m
2  
(×1
00
) Macrophages
–
–
– –
–
+ +
+
+
++–
– –
– –
–
– –
–
+ +
+
+
++–
– –
–IGF-1
JB3 (loc)
JB3 (sys)
Figure 2. The IGF-1 receptor (IGF-1R) antagonist JB3 differentially influences local inflammation and healing outcome depending on the route of
administration. (a) IGF-1R–positive cells were significantly increased in IGF-1–treated ovariectomized (Ovx) wounds, but were unchanged with 17b-estradiol
treatment (þ E2). (b) Representative immunohistochemistry for wound IGF-1 receptor (IGF-1R; arrows, positive cells). Local JB3 blocks IGF-1’s healing-
promoting effects, whereas systemic JB3 does not, quantified by (c) wound area and (d) re-epithelialization. (e) Representative hematoxylin and eosin–stained
sections of incisional wounds (day 3; arrows, wound margins). (f) Neither systemic nor local JB3 treatment altered IGF-1’s anti-inflammatory potential with
respect to neutrophils, whereas (g) systemic, but not local, JB3 prevented IGF-1-mediated reduction in wound macrophages. Systemic JB3 alone (g) further
increased wound macrophage influx, but (f) had no effect on neutrophils. Meanþ SEM, n¼5–6 per group. *Po0.05. (b) Bar¼ 25mm; (e) bar¼ 500mm.
www.jidonline.org 2841
E Emmerson et al.
IGF-1 Promotes Cutaneous Healing in Ovx Mice
ERα dermis
ERα epidermis
ERβ dermis
ERβ epidermis
10 8
*
* *
6
2
0Ce
lls
 p
er
 m
m
2  
(×1
,0
00
)
Intact Ovx +IGF-1
4
6
8
4
2
0
4 6
Ce
lls
 p
er
 m
m
2  
(×1
,0
00
)
4
2
0
Intact Ovx +IGF-1
In
te
ns
ity
3
2
1
0
Wound area
MacrophagesNeutrophils
2.5
*
*
100
80
60
40
20
0
%
2
1.5
Ar
ea
 (m
m2
)
1
0.5
0
10
Ce
lls
 p
er
 m
m
2  
(×1
00
)
8
6
4
2
0
IGF-1
IGF-1
ICI
ICI
–
–
–
+
10
8
6
4
2
0
+
+
–
–
–
+ +
+ –
–
–
+ +
+
–
–
–
+ +
+
% Re-epithelialization
Intact
Intact
Intact
Ovx
Ovx
+IGF-1
+IGF-1
Intact
Intact
+IGF-1
+IGF-1
Ovx
Ovx
Ovx +IGF-1
Intact Ovx +IGF-1C
el
ls 
pe
r m
m
2  
(×1
,0
00
)
Figure 3. IGF-1 modulates local estrogen receptor (ER) expression, with IGF-1 effects on healing being partially ER dependent. (a–d) Local IGF-1 has no
effect on cutaneous ERa expression but significantly increases the number of ERb-expressing wound cells. (e–h) Representative immunohistochemistry for
ERa (e, dermis; g, epidermis) and ERb (f, dermis; h, epidermis). Arrows indicate positive cells. (i–l) ICI partially blocks the healing-promoting effects of IGF-1,
quantified by (i) a significant increase in wound area and (l) macrophage recruitment versus IGF-1-treated ovariectomized (Ovx) mice. ICI had no effect on
(j) re-epithelialization or (k) neutrophil influx. Meanþ SEM, n¼5–6 per group. *Po0.05. (e, f) Bar¼25 mm; (g, h) bar¼50 mm.
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retard migration with 107 M IGF-1 (fibroblasts and keratino-
cytes), excluding the possibility of cross-reactivity with the
insulin receptors (data not shown). In this case, cotreatment
with the IGF-1R antagonist JB3 failed to retard migration,
while the ERa-selective antagonist MPP entirely inhibited
IGF-1’s effects on migration. The fact that the effects of IGF-1
on fibroblast migration appear to be mediated through ERa
(Figure 6b and d) suggests an important role for fibroblasts in
the ERa/ mouse delayed wound closure phenotype
(Figure 4). Finally, the anti-inflammatory effect of IGF-1 on
lipopolysaccharide-stimulated murine peritoneal macro-
phages appears to be predominantly mediated by ERa.
Specifically, IGF-1 dampened lipopolysaccharide-induced
expression of the proinflammatory cytokines macrophage
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Figure 6. Cell-specific roles for IGF-1 receptor (IGF-1R) and estrogen receptors (ERs) are confirmed in vitro. (a) IGF-1–promoted human keratinocyte ‘‘scratch
wound’’ migration in vitro was inhibited by coincubation with IGF-1R antagonist but not ERa- or ERb-selective antagonists. (b) By contrast, IGF-1–promoted
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migration inhibitory factor (Figure 6e), tumor necrosis factor-
a (Figure 6f), and interleukin-1b (not shown). Although IGF-
1R and ERb antagonist cotreatment showed no difference in
expression, cotreatment with the selective ERa antagonist
MPP entirely blocked the in vitro anti-inflammatory effects of
IGF-1 (Figure 6e and f). Again, these data are consistent with
ERa mediating IGF-1’s anti-inflammatory effects in vivo
(Figure 4c).
DISCUSSION
The effects of IGF-1 on cutaneous wound healing are unclear,
with studies variably reporting benefits (Beckert et al., 2005;
Semenova et al., 2008) or no effects (Breuing et al., 1997;
Dunaiski and Belford, 2002). Here, we show that local
administration of the stable long R3 form of IGF-1 strongly
accelerates cutaneous repair in estrogen-deficient mice, a
physiologically relevant model of human age–associated
delayed healing. Although links between IGF-1 and estrogen
deprivation have previously been described in liver and bone
(Kasukawa et al., 2002; Lindberg et al., 2006; Govoni et al.,
2008; Fritton et al., 2010), to our knowledge this is previously
unreported in skin.
Our data are consistent with a role for endogenous IGF in
counteracting deficiency in estrogen. This is not a new
concept and has been suggested in the context of both natural
cycling and menopause (Fritton et al., 2010; Della Torre
et al., 2011). Indeed, serum IGF-1 reportedly increases during
the estrus (low estrogen) phase of the goat reproductive cycle
(Hashizume et al., 2000) and following ovariectomy in
female rodents (Barengolts et al., 1996; Govoni et al., 2008)
and humans (Fogle et al., 2008; Nar et al., 2009). On the
basis of our observations, we hypothesize that IGF-1 may
partially compensate for lack of estrogen in the skin of Ovx
mice and postmenopausal women. This fits with a sharp
increase in wound macrophages following IGF-1R antagon-
ism over and above that observed in Ovx mouse wounds
(Figure 2g).
IGF-1 has been linked to inflammation in numerous tissue
systems, contributing to tissue repair in injured muscle (Lu
et al., 2011) and heart (Kluge et al., 1995), and associated
with inflammation of the airway in asthma patients (Yama-
shita et al., 2005) and the intestine in inflammatory bowel
disorder patients (Eivindson et al., 2005). Moreover, local
IGF-1 attenuates tumor necrosis factor-a and interleukin-1b
production in rat burn wounds (Spies et al., 2001), whereas
cerebral IGF-1 reduces proinflammatory cytokine expression
in lipopolysaccharide-treated mice (Park et al., 2011). A
central theme in the development and progression of chronic
wounds is an inappropriately excessive inflammatory re-
sponse that fails to resolve (Loots et al., 1998). On the basis of
the above-mentioned observations and our data, we propose
that local IGF-1 administration would be of benefit in chronic
wound patients.
In the Ovx wound model, we see clear uncoupling of
IGF-mediated healing promoting and anti-inflammatory
effects. Local IGF-1R antagonism (via JB3) attenuated the
healing-promoting action of IGF-1, particularly with respect
to re-epithelialization, without influencing inflammation.
Conversely, systemic IGF-1R antagonism (via JB3) did not
alter overall healing but had a pronounced effect on wound
inflammation. IGF-1R is expressed in both keratinocytes
(DiGiovanni et al., 2000) and fibroblasts (Figure 1), and our
in vitro experiments suggest an important role for keratino-
cytes in the local IGF-1R-mediated beneficial effects on
healing.
Our data provide a previously unreported clue that the
reported beneficial effects of IGF-1 on cutaneous wound
healing may in fact be mediated not entirely by IGF-1R but by
ERs. A number of studies report that IGF-1 can signal via the
ERs (Aronica and Katzenellenbogen, 1993; Klotz et al., 2000,
2002), in particular ERa, which is required for IGF-induced
proliferation in the uterus (Klotz et al., 2002). Interactions
between ERa and IGF-1 have also been demonstrated in
numerous other organ systems, including the breast (Surmacz
and Bartucci, 2004), brain (Marin et al., 2009), and liver
(Della Torre et al., 2011). Far fewer associations have been
made between ERb and IGF-1 (e.g., Rivadeneira et al., 2006).
Mechanistically, 17b-estradiol induces phosphorylation of
the IGF-1R and rapid binding of ERa to the IGF-1R in vitro,
whereas there is no such activity with ERb (Kahlert et al.,
2000). Crucially, ERa is required to induce the estrogen-
responsive element in IGF-1-stimulated cells (Kahlert et al.,
2000). In this study, we provide evidence that ERa is required
for IGF-1 to promote cutaneous healing in Ovx mice. When
we investigate this further in cell-specific ERa-null mice, it
becomes apparent that epidermal ERa is important for overall
healing. By contrast, ERa must be present in both the
epidermis and inflammatory cells for IGF-1 to elicit its anti-
inflammatory effects.
In this study, we demonstrate that IGF-1, similar to 17b-
estradiol, and the selective estrogen receptor modulators
tamoxifen, raloxifene, and genistein (Hardman et al., 2008;
Emmerson et al., 2010), specifically induces cellular ERb in
the wound granulation tissue and wound-edge keratinocytes.
Despite our data highlighting the importance of IGF-1/ERa
cross talk in healing outcome, it is likely that local induction
of ERb may be equally important in the correct circum-
stances, given our previous observations on ERb’s beneficial
effects during wound repair (Ashworth et al., 2008; Campbell
et al., 2010). Here it is pertinent to note that the skin is able to
synthesize local steroid hormones, including 17b-estradiol,
de novo, independent of systemic levels (reviewed in
Emmerson and Hardman, 2012), possibly leading to 17b-
estradiol/ER signaling in the skin of Ovx mice. However, the
activities of the enzymes required are significantly reduced or
are lacking in most tissues following ovariectomy (Samy
et al., 2003; Zhou et al., 2010). We also note that the
phytoestrogen genistein promotes wound repair in Ovx mice
via multiple mechanisms, including the IGF-1R, primarily
influencing keratinocyte migration and subsequent wound re-
epithelialization (Emmerson et al., 2010).
IGF signaling is exceptionally complicated: IGF-1 can also
signal through the insulin receptor; however, the affinity is
several times less than that of insulin. The action of IGFs
through the IGF receptors is mediated by six high-affinity
binding proteins (IGFBPs), with some inhibiting IGF actions
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and others moderating (reviewed in Mohan and Baylink,
2002). In addition, IGFBP proteases modulate the actions of
IGFBPs by cleaving to form binding proteins that have
reduced or no affinity for IGFs. Of particular note, this study
uses long arginine (LR3) IGF-1, which is generally accepted
to be a stable IGF analog, with a longer half-life of
20–30 hours (von der Thusen et al., 2011) and three times
more potency than IGF-1 (Tomas et al., 1992). Long-R3-IGF-I
has very low affinity for the IGFBPs but retains its ability to
bind to the IGF-1R (Pampusch et al., 2005). However, this
low affinity is reported to accelerate clearance of exogenous
growth factors from implanted wound fluid collection
chambers, although by 24 hours post treatment IGF-1 and
LR3 IGF-1 remain in equal amounts (Robertson et al., 1999).
Although we have not profiled the LR3 IGF-1 kinetics, we do
observe clear efficacy with respect to wound healing
following two 24-hour administrations.
In conclusion, the effects of IGF-1 on cutaneous repair are
clearly mediated via multiple receptors (Supplementary Figure
S1 online). We provide strong evidence for ER/IGF-1R cross
talk in the skin, and demonstrate that IGF-1 promotes healing
in hormonally deprived mice. These findings suggest that
estrogen and IGF-1 may compensate under specific circum-
stances, signaling a change in the way we think about
postmenopausal pathology, with important implications for
the future treatment of delayed healing post menopause.
MATERIALS AND METHODS
Wounding experiments
Ten-week-old female C57BL/6 mice with intact ovaries and ten-
week-old C57BL/6 mice that had undergone ovariectomy (see
Supplementary methods online) were wounded following our esta-
blished protocol (see Supplementary methods online; in accordance
with Home Office regulations, Project Licence 40/3203). On the day
of wounding, Ovx mice were injected subcutaneously (s.c.) at the
wound site with 10 mg per wound of long R3 IGF-1 (Novozymes,
Bagsvaerd, Denmark) dissolved in 5% DMSO/95% corn oil or
vehicle alone. Further injections were administered 1 day after
wounding (day 1). In addition, Ovx mice were treated with IGF-1
plus 15 mg kg1 per day local JB3 (custom made, Invitrogen, Paisley,
UK), IGF-1 plus 30 mg kg1 per day s.c. systemic JB3 (Haylor et al.,
2000) or systemic JB3 alone (ventral side), on the day before
wounding (day 1), day of wounding (day 0) and the 2 days post
wounding (days 1 and 2), or IGF-1 plus 2mg kg1 per day s.c.
systemic ICI 182780 (Tocris, Bristol, UK, ventral side) on days 1, 0,
and 1. Estrogen-treated mice were treated at the time of wounding
with the s.c. implantation of a 0.05-mg, 21-day, slow-release
17b-estradiol pellet (Innovative Research of America, Sarasota, FL).
ERa/ and ERb/ mice were bred from heterozygote breeding
pairs as previously described (Dupont et al., 2000) and genotyped at
weaning age. Epidermal-specific and inflammatory cell–specific ERa-
null mice were generated as previously described (Campbell et al.,
2010). Female wild-type littermates were used as controls. Ovar-
iectomy and IGF-1 injection were carried out as described above.
Histology and immunohistochemistry
Histological sections were prepared from wound tissue fixed in 10%
buffered formalin saline and embedded in paraffin wax. Five-
micrometer sections were stained with hematoxylin and eosin or
subjected to immunohistochemistry with rat anti-Ly6G, rat anti-Mac-3,
anti-ERa rabbit polyclonal antibody (Santa Cruz, Santa Cruz, CA),
mouse monoclonal anti-ERb antibody (Serotec, Oxford, UK), goat
polyclonal IGF-1 antibody (Santa Cruz), or rabbit polyclonal IGF-1R
antibody (Santa Cruz), and the appropriate biotinylated secondary
antibody, followed by ABC-peroxidase reagent (Vector Laboratories,
Peterborough, UK) with Novared substrate and counterstaining
with hematoxylin. Total cell numbers, wound area, and percentage
re-epithelialization were quantified with the Image Pro Plus
software (see Supplementary methods online; MediaCybernetics,
Silver Spring, MD).
Peritoneal macrophage isolation and culture
Peritoneal macrophages were isolated from adult female C57BL/6
mice by intra-peritoneal lavage with cold sterile PBS, and pooled,
as previously described (Emmerson et al., 2009). Cell viability was
determined using Trypan blue. A total of 106 cells per 400ml in
suspension in serum-free phenol red–free RPMI 1640 medium
(Invitrogen) were treated with lipopolysaccharide (10 mgml1) and
IGF-1 (107 M), IGF-1 plus JB3 (109 M) as previously used
(Emmerson et al., 2010), IGF-1 plus PHTPP (105 M; Tocris), or
IGF-1 plus MPP dihydrochloride (105 M; Tocris) as previously used
(Campbell et al., 2010), for 16 hours at 37 1C and 5% CO2.
Following incubation, the supernatant was aspirated and 500ml
TRIzol (Invitrogen) added to each well. Cells were detached using a
cell scraper and stored at 20 1C.
Cell assays
Primary human epidermal keratinocytes and dermal fibroblasts
(isolated from females) were supplied by XCellR8 and Epistem
(Manchester, UK), respectively. Cell-based assays were performed in
phenol red–free media (Lonza, Berkshire, UK; Lifeline, Walkersville,
MD) containing charcoal-stripped serum (Invitrogen).
Two-dimensional migration assay
Eighty-percent–confluent dermal fibroblast or ninety-percent–con-
fluent epidermal keratinocyte sheets were ‘‘scratch wounded’’ using
the point of a sterile 1,000-ml volume pipette tip. Cells were
incubated in serum- and PSA-(CellnTech, Bern, Switzerland)
supplemented DMEM (Lonza) or keratinocyte media (Lifeline)
containing IGF-1 (107 M), IGF-1 plus JB3 (109 M), or PHTPP
(105 M; Tocris) or MPP dihydrochloride (105 M; Tocris) at 37 1C and
5% CO2 for 24 (fibroblasts) or 72 hours (keratinocytes). Cells were
washed and visualized with crystal violet.
Quantitative real-time qPCR
Total RNA was isolated from treated mouse macrophages as
previously described (Emmerson et al., 2009) using the Purelink
RNA MiniKit (Invitrogen). cDNA was transcribed from 1 mg of RNA
(Transcriptor, Roche, West Sussex, UK) and quantitative real-time
PCR performed using the SYBR green I core kit (Eurogentec,
Southampton, UK) and an Opticon qPCR thermal cycler (Bio-Rad,
Hertfordshire, UK). Each sample was serially diluted over three
orders of magnitude, and for each primer all samples were analyzed
on the same 96-well plate. Primer sequences are listed in
Supplementary Table S1 online. Gene expression was determined
relative to a standard sample and normalized using a value derived
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from the housekeeping genes Gapdh and Ywahz (Turabelidze
et al., 2010).
Statistical analysis
Statistical differences were determined using analysis of variance,
Mann–Whitney U-test, and Tukey’s q test (SIMFIT, University of
Manchester). A P-value of o0.05 was considered significant.
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